UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2301-3
Program Prior Authorization/Medical Necessity
Medication Filspari™ (sparsentan)
P&T Approval Date 4/2023, 10/2024, 06/2025, 6/2025
Effective Date 9/1/2025
1. Background:
Filspari (sparsentan) is indicated to slow kidney function decline in adults with primary
immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.
2. Coverage Criteriaa:
A. Initial Authorization
1. Filspari will be approved based on all of the following:
a. Diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by renal
biopsy
-AND-
b. Patient is at risk of disease progression
-AND-
c. Used to slow kidney function decline
-AND-
d. Used to reduce proteinuria
-AND-
e. Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2
-AND-
f. Both of the following:
1) Patient is on a maximized stable dose with one of the following prior to initiating
therapy:
a) maximally tolerated angiotensin converting enzyme (ACE) inhibitor (e.g.,
captopril, enalapril)
© 2025 UnitedHealthcare Services Inc.
1
b) maximally tolerated angiotensin II receptor blocker (ARB) (e.g.,
candesartan, valsartan)
-AND-
2) Use of renin-angiotensin-aldosterone system (RAAS) inhibitors (e.g., ACE
inhibitors, ARBs), endothelin receptor antagonists [(ERAs) e.g., Letairis,
Opsumit, Tracleer)], and Tekturna will be discontinued prior to initiating
treatment
-AND-
g. History of failure, contraindication or intolerance to a 30-day trial of a glucocorticoid
(e.g., methylprednisolone, prednisone)
-AND-
h. Prescribed by or in consultation with a nephrologist
Authorization will be issued for 12 months
B. Reauthorization
1. Filspari will be approved based on the following:
a. Documentation of positive clinical response demonstrated by a reduction in
proteinuria
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Filspari [package insert]. San Diego, CA: Traverse Therapeutics, Inc; April 2025.
2. KDIGO 2021 Glomerular Diseases Guideline. October 2021; 100 (4S).
© 2025 UnitedHealthcare Services Inc.
2
Program Prior Authorization/Medical Necessity – Filspari
Change Control
Date Change
4/2023 New program
10/2024 Updated disease progression criteria and criteria that use is to slow
kidney decline. Updated references.
6/2025 Updated references.
© 2025 UnitedHealthcare Services Inc.
3